HCPLive Network
PERSONAL FINANCE

Celgene Sell Off “Overdone”

Laura Joszt | Friday, June 22, 2012
While Onyx Pharmaceuticals is flying high on good news for its blood cancer drug, Celgene wasn’t quite so lucky. Celgene’s stock took a big hit on Thursday when it withdrew its application for Revlimid. And by the end of the week, the stock hadn’t recovered much.
 
When the European Medicine’s Agency (EMA) indicated it wanted more data on Revlimid’s application to be used on newly diagnosed multiple myeloma patients and as a maintenance therapy, Celgene withdrew the application. When news broke, its stock dropped 11.65% at the opening bell on Thursday.
 
By the end of the day Friday, the stock had only recovered slightly, up 3.68%, but still down by 8.19% over where it had closed on Wednesday afternoon.
 
 
However, investors might be a little trigger happy with Celgene. For one, the company could still resubmit to EMA. Also, a trial combining Onyx’s Kyprolis with Revlimid and Dexa revealed that patients had a 98% response rate and a 92% progression-free survival rate.
 
Revlimid is already an approved blood cancer drug — the company is simply looking to expand its use. Plus, the drug could also have a number of other uses, such as lymphoma and CLL. Another Celgene drug could be approved for a second use this year.
 
According to SeekingAlpha, the sell off could nicely benefit investors who take advantage of it to buy up shares. Robert W. Baird released a note that it believed the sell off was overdone. The wealth management company has set a price target at $78.
 
The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.
 
Read more:


RELATED ARTICLES
The end of the year has a number of significant financial implications that we should not lose sight of in our merriment. And being aware of some of them will allow us to feel better and maybe save some money, even if we are sometimes profligate in our holiday shopping.
While planning to reduce your taxable income is important, it is equally imperative that you take advantage of the multitude of federal and state tax credits that are available.
Should employed physicians unionize? The question arises as more and more physicians become employees of large organizations.
RECENT CLINICAL ARTICLES
Around 10% of elders experience some form of elder abuse (physical, sexual or emotional abuse; neglect, exploitation, or abandonment), and elders who are abused appear to have a high level of comorbidity. Evidence suggests that patients who have experienced elder abuse are at higher risk of cardiovascular-related mortality.
The American Society for Reproductive Medicine (ASRM) published a 2013 guideline addressing the number of embryos to transfer. Its guideline relied on empiric data to individualize patient care while minimizing the risk of high-order multiple births.
Variations of an enzyme could help health care professionals identify patients more likely to be diagnosed with a rare rheumatologic condition.